Sundern Sauerland

This research aims to evaluate participant satisfaction with subcutaneous ocrelizumab treatment in people with Multiple Sclerosis MS over a 12-month period. It will also investigate changes in neurofilament light chain NfL protein levels, a marker related to MS disease activity, and explore correlations between NfL levels and various clinical and imaging factors. The study is observational and follows participants who are starting ocrelizumab SC as part of their routine MS care. Participants will receive ocrelizumab as a subcutaneous injection according to their physicians discretion and local clinical practice. The study observes participants for up to 12 months to assess treatment satisfaction using the Therapy Administration Satisfaction Questionnaire for Subcutaneous administration TASQ-SC and other satisfaction questionnaires. Blood samples will be collected at baseline, month 6, and month 12 to measure NfL protein levels and other biomarkers. The study also monitors MS relapses, disability scores, and adverse events during this period. Throughout the 12 months, participants will undergo assessments of treatment satisfaction at multiple time points, including after the first injection, 6 months, and 12 months. Clinical evaluations, questionnaires, and blood tests will be conducted to track disease activity and participant experience. Researchers will measure satisfaction levels, changes in NfL concentrations, relapse rates, disability progression, and safety events. The study is designed to provide real-world data on patient experience and biomarker changes with subcutaneous ocrelizumab treatment in MS.

Researchers are conducting a prospective, observational study to collect real-world evidence on the use and dose adjustment of SL-APO sublingual apomorphine for treating OFF episodes in Parkinsons disease. The study aims to understand how SL-APO is used in practice, focusing on dose titration, individual dose determination, and how these factors influence patient satisfaction, treatment continuation, and the balance between effectiveness and safety. Participants start with a 10 mg dose of SL-APO during an OFF episode and undergo dose titration at home if the initial response is insufficient. Dose adjustments occur in 5 mg increments up to a maximum of 30 mg per dose, with no more than five doses daily and a minimum 2-hour interval between doses. The study includes a baseline visit, titration follow-up visits which may be calls or on-site, and maintenance dose tracking using patient diaries. Follow-up visits occur at 3 and 6 months, with the 6-month visit marking the studys end. During the study, participants keep a Patient Titration Diary from the second SL-APO intake until titration ends and then a Patient Maintenance Diary until study completion. Diaries document daily intake for the first week with at least 10 doses, then weekly entries. Researchers collect data on dose usage, dose adjustments, and patient outcomes without additional procedures beyond routine care. The primary outcome is identifying the most frequent dose used after adjustment, with safety and efficacy monitored through regular follow-ups over six months.